Rapamycin: A New String to the Antiproteinuric Bow?

[摘要] Progressive renal disease in the presence of proteinuria is characterized by an infiltration of inflammatory cells into the renal interstitium associated with incremental atrophy of tubular structures and replacement of the tubulointerstitium by fibrous scar. This process is commonly known as proteinuric nephropathy, a term intended to distinguish this pathology from that of the initial glomerular or other renal injury responsible for its initiation. The pathophysiological processes underlying the development of proteinuric nephropathy have been extensively studied. As a result, a variety of general antiproteinuric strategies, supported by high-level evidence, have been introduced into clinical practice designed to slow the progression of a diverse range of primary renal diseases linked only by the commonality of proteinuria (1). Their widespread introduction into the clinic over the last 10 yr or so has been widely embraced and can be considered a spectacular success. Enthusiasm for these new treatments is also greatly encouraged by observations that for the first time, in some patients at least, regression of renal fibrosis may be possible (2). Indeed, their development vindicates the current scientific approach to medical research where intensive and careful investigation at the bench and in animals eventually translates into meaningful therapeutic interventions at the bedside.

[学科分类] 泌尿医学

[关键词] Bone marrow necrosis;Sickle cell disease;Hyperhemolysis syndrome